This website uses cookies
Read our Privacy policy and Terms of use for more information.
Aug 11, 2026
AI-designed viruses work in the lab, Replimune wins accelerated approval, Takeda targets narcolepsy at its source, and biotech IPOs rebound.
Aug 6, 2026
California rejects a pharma duty to innovate as KKR buys Integer, Pfizer expands cuts, and Lilly outpaces Novo in the GLP-1 race.
Aug 4, 2026
AstraZeneca and BMS reportedly explore a $400B combination as Curium buys Lantheus and Novo’s ziltivekimab misses Phase 3.
Jul 30, 2026
Altimmune’s obesity drug reduces heavy-drinking days, Freenome wins FDA approval, and mosquitoes expand the infectious-disease map.
Jul 28, 2026
HHS joins the $5B Genesis Mission, Lilly reports retatrutide data, Argenx buys Forte, and FDA advisers reconsider popular peptides.
Jul 23, 2026
Novo sues Lilly over Zepbound advertising, Repligen buys BioLife for $1.5B, and Big Pharma embraces psychedelic medicines.
Jul 21, 2026
Samsung Biologics makes a $1.8B peptide acquisition, Lilly expands into psychedelics, Merck launches the first oral PCSK9 drug, and Kalshi brings betting to clinical trials.
Jul 16, 2026
Chai Discovery reaches a $3.8B valuation as biotech enters earnings season alongside major AI deals, FDA approvals and billion-dollar licensing agreements.
Jul 14, 2026
Cyclospora spreads across 31 states, Sanofi earns a first-of-its-kind FDA approval, and five emerging biotech hubs challenge Boston and San Francisco.
